Table 2.

CSC specific small therapeutic agents and their delivery.

Sr. no.	Anti-CSCs strategies	Drugs/Therapeutic agent	Nanocarriers based delivery system used for the therapeutic agents	CSC source and specific marker	References
1.	Selective inhibition of Human multiple CSCs	Phenformin	Polymeric micelles using PEG-b-PAC and PEG-b-PUC 102 nm particle	Lung cancer, H460 cells, CD133+ human lung cancer mouse model	Krishnamurthy et al., 2014
2.	Selective inhibition of CSCs	Salinomycin	SAL-SWNTCHI-HA complexes; self-assembled nanoparticles from iTEP; nanogel-drug conjugates based on membranotropic CHA	Gastric cancer, AGS cells, CD44+; murine breast cancer, 4T1 cells, CD44+CD24–; breast cancer, MDA-MB-231 cells, CD44+	Wei et al., 2013; Yao et al., 2014; Zhao et al., 2014
3.	Enhanced accumulation of drug molecules in CSCs	Oxaliplatin	CSO-SA polymeric micelles	Colorectal cancer, HT29 and SW620 cells, CD133+/CD24+	Wang et al., 2011
4.	Suppression of IGF and STAT3; blockage of Hedgehog pathway	Curcumin	NanoCurc™; stearic acid-g-chitosan oligosaccharide (CSO-SA) polymeric micelles	Brain cancer, DAOY cells, etc., CD133+; colorectal cancer, patient-derived cells, CD133+/CD24+	Lim et al., 2011; Wang K. et al., 2012
5.	Inhibition Hedgehog (Hh) signaling pathway	Cyclopamine	HPMA-based delivery system	Prostate cancer, RC-92a/hTERT cells, CD133+/integrinα2β1hi	Zhou et al., 2012
6.	Selective inhibition of basal-like triple negative breast cancer CSCs	Bortezomib	Poly(ethylene glycol)-b-poly(d, l-lactide) (PEG-PLA) nanoparticles	Breast cancer, SUM159, and HCC1973 cells, ALDH+	Shen et al., 2015
7.	Increased accumulation of chemical drug within CSCs	Doxorubicin	Endosomal pH-responsive DOX-Hyd@AuNPs	Breast cancer, MDA-MB-231 cells, etc., CD44+CD24−ALDH+	Sun T. M. et al., 2014
8.	Increased accumulation of chemical drug within CSCs	Epirubicin	Nanodiamond drug complex	Murine hepatocellular carcinoma, LT2-MYC cells, MYC+	Wang H. X. et al., 2014